drugset / Trial / NCT00269087

GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

NCT00269087 ↗

Phase 3 Completed 122 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times. Subjects will be given breathing tests, and will record their breathing symptoms daily on diary cards.

Timeline

Start
2005-01-28
Primary completion
2006-10-01
Completion
2006-10-25

Publications

  • Background This study has not been published in the scientific literature.

Drugs

EvaluationDrugModalityDoseRoute
Subject fluticasone propionate/salmeterol Unknown 50 ug —
Subject fluticasone propionate/salmeterol Unknown 500 ug —